Last reviewed 2026-05-14 · How we verify

Mycophenoate Mofetil

Mycophenolate mofetil inhibits inosine monophosphate dehydrogenase (IMPDH), selectively suppressing T and B lymphocyte proliferation to prevent immune rejection.

Mycophenolate mofetil inhibits inosine monophosphate dehydrogenase (IMPDH), selectively suppressing T and B lymphocyte proliferation to prevent immune rejection. Used for Prevention of organ transplant rejection (renal, cardiac, hepatic), Active lupus nephritis, Autoimmune conditions requiring immunosuppression.

At a glance

Mechanism of action

Mycophenolate mofetil is a prodrug that is rapidly hydrolyzed to mycophenolic acid (MPA), which preferentially inhibits IMPDH type II, an enzyme critical for guanosine nucleotide synthesis in lymphocytes. By depleting guanosine nucleotides, MPA selectively suppresses T and B cell proliferation while having minimal effects on other cell types, making it an effective immunosuppressant for preventing organ transplant rejection and treating autoimmune conditions.

Approved indications

• Prevention of organ transplant rejection (renal, cardiac, hepatic)
• Active lupus nephritis
• Autoimmune conditions requiring immunosuppression

Common side effects

• Gastrointestinal disturbances (diarrhea, nausea, vomiting, abdominal pain)
• Leukopenia
• Anemia
• Infection
• Headache
• Tremor

Key clinical trials

• Study Comparing Efficacy and Safety of Mycophenolate Mofetil (Cellcept) With Delayed Introduction of Sirolimus and Discontinuation of Cyclosporine, With Those of Mycophenolate Mofetil and Long Term Continuation of Cyclosporine in Renal Transplant Recipients (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Mycophenoate Mofetil CI brief — competitive landscape report
• Mycophenoate Mofetil updates RSS · CI watch RSS
• Hoffmann-La Roche portfolio CI